Examkin

Question

Difficulty: MediumInfectious Diseases

Match each clinical presentation of a suspected or confirmed systemic fungal infection with its most appropriate first-line targeted therapy or initial empiric management strategy.

  • A 38-year-old cave explorer from the Ohio River Valley presents with weeks of fever, dry cough, and hepatosplenomegaly. Urine antigen testing is positive for an endemic fungus.Oral itraconazole
  • A 31-year-old man with advanced HIV (CD4 count 45 cells/µL) presents with a severe headache. Cerebrospinal fluid analysis reveals an opening pressure of 300 mm H2O and encapsulated yeast.Intravenous liposomal amphotericin B and flucytosine
  • A 58-year-old man with diabetic ketoacidosis presents with periorbital pain, facial swelling, and a necrotic nasal eschar. Biopsy shows broad, nonseptate hyphae branching at right angles.Urgent surgical debridement and intravenous liposomal amphotericin B
  • A 45-year-old woman with profound neutropenia following chemotherapy develops pleuritic chest pain and hemoptysis. Chest computed tomography reveals a pulmonary nodule surrounded by a ground-glass opacity (halo sign).Intravenous voriconazole
  • A 52-year-old critically ill patient receiving total parenteral nutrition via a central venous catheter develops new-onset fever, hypotension, and peripheral blood cultures positive for yeast.Intravenous echinocandin and central venous catheter removal

Answer

Histoplasmosis is treated with oral itraconazole. Cryptococcal meningitis induction requires intravenous liposomal amphotericin B and flucytosine. Rhinocerebral mucormycosis requires urgent surgical debridement and intravenous liposomal amphotericin B. Invasive aspergillosis is treated with intravenous voriconazole. Candidemia associated with a central line requires an intravenous echinocandin and central venous catheter removal.
Each fungal pathogen has a highly specific first-line therapeutic approach determined by clinical trials and current guidelines. Itraconazole is standard for mild-to-moderate histoplasmosis. Cryptococcal meningitis necessitates dual therapy (amphotericin B + flucytosine) for rapid CSF sterilization. Mucormycosis uniquely requires surgical intervention alongside amphotericin B due to its angioinvasive, necrotic nature. Voriconazole provides optimal outcomes for invasive aspergillosis. Candidemia in critical illness requires line removal and an echinocandin due to rising non-albicans azole resistance.

Step-by-Step Solution

1
Analyze the cave explorer vignette (Histoplasmosis).
Identify the endemic exposure (spelunking, Ohio River Valley) and positive urine antigen as mild-to-moderate histoplasmosis.
Matching to the appropriate antifungal step-down or outpatient therapy, which is oral itraconazole.
2
Analyze the advanced HIV vignette (Cryptococcosis).
Identify the encapsulated yeast in cerebrospinal fluid with high opening pressure as Cryptococcal meningitis.
Requires aggressive fungicidal induction therapy capable of penetrating the central nervous system, specifically liposomal amphotericin B and flucytosine.
3
Analyze the diabetic ketoacidosis vignette (Mucormycosis).
Correlate the necrotic eschar and broad, nonseptate right-angle branching hyphae with rhinocerebral mucormycosis.
Antimicrobial therapy alone is insufficient; matching requires acknowledging the necessity of urgent surgical debridement combined with liposomal amphotericin B.
4
Analyze the neutropenic host vignette (Aspergillosis).
Recognize the classic 'halo sign' and hemoptysis in a severely neutropenic patient as invasive pulmonary aspergillosis.
Voriconazole is superior to amphotericin B for the targeted treatment of invasive Aspergillus infections.
5
Analyze the critically ill patient vignette (Candidemia).
Identify bloodstream yeast in the setting of total parenteral nutrition and a central line as candidemia.
Demands source control via catheter removal and an echinocandin to cover fluconazole-resistant species like Candida glabrata and Candida krusei.

Key Concept

Selecting the correct targeted antifungal therapy or management strategy based on specific clinical presentations, host immune status, and fungal morphologic characteristics.
Estimated Time:1m 30s
Rate this question

Topics

Infectious Diseases

More questions from this topic